Drug Trial Radar · NCT03131648
Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)
Last checked: Nov 20, 2026Latest source record: Mar 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
802
Actual
Start
May 30, 2017
Primary completion
Aug 7, 2018
Study completion Oct 10, 2019
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Apr 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary objective: To evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe atopic dermatitis (AD). Secondary objectives: To evaluate the efficacy of tralokinumab on severity and extent of AD, itch, and health related quality of life compared with placebo. Maintenance objective: To evaluate maintenance of effect with continued tralokinumab dosing up to 52 weeks compared to placebo for subjects achieving clinical response at Week 16.
Conditions
- Atopic Dermatitis
Interventions
TralokinumabDrug
Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
PlaceboDrug
Placebo contains the same excipients, in the same concentration only lacking tralokinumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16Time frame: At Week 16
- Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 16Time frame: At Week 16
Locations
123 sites in 5 countries. Site status is shown where the registry gives one.
Clinical Research Center of Alabama
Birmingham, Alabama
Tien Q. Nguyen, MD, Inc.
Fountain Valley, California
Dermatology Research Associates
Los Angeles, California
Quest Dermatology Research
Northridge, California
Dermatology Specialists, Inc.
Oceanside, California
Center for Dermatology and Laser Surgery
Sacramento, California
University Clinical Trials, Inc.
San Diego, California
The GWU Medical Faculty Associates
Washington D.C., District of Columbia
Skin Care Research, Inc.
Boca Raton, Florida
Park Avenue Dermatology
Orange Park, Florida
Forward Clinical Trials
Tampa, Florida
Research Institute of the Southeast, LLC
West Palm Beach, Florida
ACRC Dermatology
West Palm Beach, Florida
Georgia Pollens Clinical Research Centers, Inc.
Albany, Georgia
Allergy Center at Brookstone Research
Columbus, Georgia
Dermatologic Surgery Specialists
Macon, Georgia
Meridian Clinical Research
Savannah, Georgia
Altman Dermatology Associates
Arlington Heights, Illinois
PMG Research of Christie Clinic
Chicago, Illinois
Deaconess Clinic
Evansville, Indiana
Skin Sciences, PLLC
Louisville, Kentucky
Clinical Trials of SWLA, LLC
Lake Charles, Louisiana
DermAssociates, PC
Rockville, Maryland
Clarkston Skin Research
Clarkston, Michigan
Derm Center
Troy, Michigan
MediSearch LLC
Saint Joseph, Missouri
JDR Dermatology Research
Las Vegas, Nevada
University at Buffalo Department of Dermatology
Buffalo, New York
Weil Cornell Medicine
New York, New York
Juva Skin & Laser Center
New York, New York
Deramatology Consulting Services, PLLC
High Point, North Carolina
Dermatologists of Greater Columbus
Bexley, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Oregon Medical Research Center
Portland, Oregon
Oregon Health & Sciences University
Portland, Oregon
UPMC Department of Dermatology
Pittsburgh, Pennsylvania
Austin Dermatology Associates
Austin, Texas
Tekton Research
Austin, Texas
Dermtology Treatment and Research Center
Dallas, Texas
Houston Skin Associates
Houston, Texas
Showing 40 of 123 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.